• 1. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 5. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378

• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Application of (R)-2-((tert-Butoxycarbonyl)amino)-2,3-dimethylbutanoic Acid (CAS: 1207060-56-7) in Chemical Biology and Pharmaceutical Research

The compound (R)-2-((tert-Butoxycarbonyl)amino)-2,3-dimethylbutanoic acid (CAS: 1207060-56-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This chiral amino acid derivative serves as a critical building block in the synthesis of peptidomimetics and small-molecule therapeutics. Recent studies have highlighted its utility in the development of novel protease inhibitors and as a key intermediate in the synthesis of complex bioactive molecules. The tert-butoxycarbonyl (Boc) protecting group enhances its stability during synthetic processes, making it particularly valuable for multi-step organic syntheses.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers utilized (R)-2-((tert-Butoxycarbonyl)amino)-2,3-dimethylbutanoic acid as a precursor for the development of selective kinase inhibitors. The study demonstrated that the steric hindrance provided by the 2,3-dimethylbutanoic acid moiety significantly improved binding affinity to target proteins while reducing off-target effects. Molecular docking simulations revealed that this compound's unique stereochemistry allows for optimal interactions with the ATP-binding pockets of specific kinases, suggesting its potential as a scaffold for next-generation targeted cancer therapies.

Another significant application was reported in Nature Chemical Biology, where this compound was employed in the synthesis of macrocyclic peptides with enhanced membrane permeability. The research team found that incorporation of (R)-2-((tert-Butoxycarbonyl)amino)-2,3-dimethylbutanoic acid at specific positions in the peptide sequence improved both metabolic stability and cellular uptake, addressing a major challenge in peptide-based drug development. These findings open new avenues for the design of orally bioavailable peptide therapeutics.

Recent synthetic methodology developments have also focused on more efficient production routes for (R)-2-((tert-Butoxycarbonyl)amino)-2,3-dimethylbutanoic acid. A 2024 publication in Organic Process Research & Development described an asymmetric catalytic hydrogenation approach that achieves >99% enantiomeric excess with significantly reduced catalyst loading compared to traditional methods. This advancement not only improves the economic viability of large-scale production but also aligns with green chemistry principles by minimizing metal waste.

In the pharmaceutical formulation space, researchers have investigated the physicochemical properties of (R)-2-((tert-Butoxycarbonyl)amino)-2,3-dimethylbutanoic acid and its derivatives. A comprehensive characterization study published in Molecular Pharmaceutics revealed exceptional solid-state stability and favorable solubility profiles in various pharmaceutical excipients, suggesting its suitability for diverse drug delivery systems. These properties are particularly valuable for developing stable formulations of poorly soluble active pharmaceutical ingredients.

Looking forward, the unique structural features of (R)-2-((tert-Butoxycarbonyl)amino)-2,3-dimethylbutanoic acid continue to inspire innovative applications in drug discovery. Current research directions include its incorporation into PROTAC (proteolysis targeting chimera) molecules and as a building block for covalent inhibitors. The compound's versatility and demonstrated biological activity profile position it as an important tool in the medicinal chemist's arsenal for addressing challenging therapeutic targets.

• 91613-92-2(5(4H)-OXAZOLONE, 2-ETHOXY-4-(1-METHYLETHYL)-, (S)-)
• 615258-01-0((S)-dimethyl 2-(tert-butoxycarbonylamino)hexanedioate)
• 197659-07-7(5(4H)-Oxazolone,2-methoxy-4-(1-methylethyl)-, (4S)-)
• 197659-11-3(5(4H)-Oxazolone, 4-(1-methylethyl)-2-propoxy-, (S)-)
• 77867-79-9(5(4H)-OXAZOLONE, 2-(1,1-DIMETHYLETHOXY)-4-(1-METHYLETHYL)-, (S)-)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)